Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Autor: Kwon, Mi, Iacoboni, Gloria, Reguera-Ortega, Juan Luis, Corral, Lucía López, Morales, Rafael Hernani, Ortiz-Maldonado, Valentín, Guerreiro, Manuel, Caballero, Ana Carolina, Domínguez, María Luisa Guerra, Pina, Jose Maria Sanchez, Mussetti, Alberto, Sancho, Juan-Manuel, Bastos-Oreiro, Mariana, Catala, Eva, Delgado, Javier, Henriquez, Hugo Luzardo, Sanz, Jaime, Calbacho, Maria, Bailén, Rebeca, Carpio Segura, Cecilia del Carmen, Ribera Santasusana, Jose Maria, Sureda, Anna, Briones Meijide, Javier, Hernandez-Boluda, Juan Carlos, Cebrián, Nuria Martínez, Martin, Jose Luis Diez, Martín, Alejandro, Barba, Pere, Universitat Autònoma de Barcelona. Departament de Medicina

Publikováno v: Haematologica. 108(1)

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aef314b3c1312babd5bb4165e73152d9
https://pubmed.ncbi.nlm.nih.gov/35770532

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

Autor: Hodkinson, Brendan P. Oncology Translational Research (Estats Units d'Amèrica), Schaffer, Michael, Brody, Joshua D., Jurczak, Wojciech, Carpio Segura, Cecilia del Carmen, Ben-Yehuda, Dina, Avivi, Irit, Forslund, Ann, Özcan, Muhit, Alvarez, John, Ceulemans, Rob, Fourneau, Nele, Younes, Anas, Balasubramanian, Sriram, Universitat Autònoma de Barcelona

Publikováno v: Translational Oncology
Translational Oncology, Vol 14, Iss 1, Pp 100977-(2021)
Scientia
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona

Highlights • Biomarkers of response to ibrutinib + nivolumab were analyzed in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma and Richter transformation. • DLBCL patients with elevated PD-L1 by immunohistochemistry tended to have bette

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa065b6f8a558595699c63e7b7068433
https://doi.org/10.1016/j.tranon.2020.100977

Inhibition of BCR Signaling Using the Syk Inhibitor TAK-659 Prevents Stroma-Mediated Signaling in Chronic Lymphocytic Leukemia Cells

Autor: Purroy, Noelia, Carabia, Júlia, Abrisqueta, Pau, Egia-Mendikute, Leire, Aguiló, Meritxell, Carpio Segura, Cecilia del Carmen, Palacio, Carles, Crespo, Marta, Bosch José, Francesc Xavier, Universitat Autònoma de Barcelona

Publikováno v: Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Repositorio Abierto de la UdL
Universitad de Lleida
Scopus-Elsevier
Recercat. Dipósit de la Recerca de Catalunya
instname
Oncotarget

// Noelia Purroy 1, * , Julia Carabia 1, * , Pau Abrisqueta 1 , Leire Egia 1 , Meritxell Aguilo 1 , Cecilia Carpio 1 , Carles Palacio 1 , Marta Crespo 1, * , Francesc Bosch 1, * 1 Laboratory of Experimental Hematology, Department of Hematology, Vall

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ee8e5d4ec5ce78dbc1b54bb40ea914c
http://hdl.handle.net/10459.1/70102